Understanding how SETD2 inactivation affects lung adenocarcinoma growth
Identifying the Impact of SETD2 Inactivation in Lung Adenocarcinoma
This study is looking at how a gene called SETD2 affects lung adenocarcinoma, a common lung cancer, and will test if certain diets and medications can help slow down tumor growth in patients with this gene issue.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10989950 on NIH RePORTER |
What this research studies
This research investigates the role of SETD2 inactivation in lung adenocarcinoma, a common type of lung cancer. It explores how the loss of SETD2 leads to increased tumor cell proliferation through changes in one-carbon metabolism and activation of specific signaling pathways. The study will involve testing dietary interventions and drugs that target the methionine cycle to see if they can effectively reduce tumor growth in patients with SETD2 deficiency. By understanding these mechanisms, the research aims to identify new treatment strategies for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung adenocarcinoma who have mutations leading to SETD2 inactivation.
Not a fit: Patients with lung adenocarcinoma who do not have SETD2 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options for patients with lung adenocarcinoma that has SETD2 inactivation.
How similar studies have performed: Previous research has shown promising results in targeting metabolic pathways in cancer, suggesting potential for success in this approach.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Feldser, David — University of Pennsylvania
- Study coordinator: Feldser, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.